Pfizer’s shares (currently trading at $26.70) have posted a disappointing 10.2% loss, well below the S&P 500’s 3.8% gain.

We recently compiled a list of the 10 Most Undervalued US Stocks to Buy According to Hedge Funds. In this article, we are ...

We recently published a list of the 11 Best Pharma Stocks to Buy According to Hedge Funds. In this article, we are going to ...

Over the past six decades, hundreds of millions of people have taken Xanax or one of its relatives in the benzodiazepine family for a range of ...

Pfizer (NYSE:PFE) stock and Arvinas (NASDAQ:ARVN) stock slip in reaction to mixed Phase 3 data for their breast cancer drug ...

Benzinga Edge's Unusual Options board spots potential market movers before they happen. See what positions big money is ...

Guggenheim analyst Vamil Divan maintained a Buy rating on Pfizer (PFE – Research Report) yesterday. The company’s shares closed yesterday at ...

Arvinas (ARVN) stock faces a downgrade after underwhelming trial data for breast cancer drug vepdegestrant developed with ...

Shares of Pfizer Inc. PFE slid 2.44% to $25.99 Tuesday, on what proved to be an all-around poor trading session for the stock ...

An experimental breast cancer treatment co-developed by Pfizer and Arvinas significantly improved the time some patients ...

Representative Jefferson Shreve (R-Indiana) recently bought shares of Pfizer Inc. (NYSE:PFE). In a filing disclosed on March ...

The general mood among these heavyweight investors is divided, with 48% leaning bullish and 37% bearish. Among these notable options, 5 are puts, totaling $799,839, and 22 are calls, amounting to ...